MPM BioImpact — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatTodd Foley· per SEC Form D
Co-investors5AM VenturesRoche Venture FundTCG CrossoverAgent Capital
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)
BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)John Hamer(Director)in
Board seatLuke Evnin· per SEC Form D
Co-investorsDCVC BioQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundDCVC (Data Collective)
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)
Board seatLuke Evnin· per SEC Form D
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesRA CapitalDCVC BioDeerfield Management Company
BiotechCambridge, US
Lloyd M. Segal(Director)
BoardBrian Goodman(Executive Officer)inMatthew Roden(Executive Officer, Director)
Board seatTodd Foley· per SEC Form D · $72M raise · filed Feb 2021
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.